Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication

Mario Scarpa(University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center), Maria R. Baer(University of Maryland, Baltimore)

Oncotarget

August 31, 2021

10.18632/oncotarget.28042

Cited by 3

Related Papers

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

|Blood|2002|365

Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator

|Clinical Cancer Research|2005|238

Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

|PLoS ONE|2013|74

PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation

|Molecular Cancer Therapeutics|2021|25

Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress

|Oncotarget|2016|22